IPO - CorMedix Inc.

Form Type: 424B5

Filing Date: 2025-06-26

Corporate Action: Ipo

Type: New

Accession Number: 000121390025058406

Filing Summary: CorMedix Inc. is offering $85 million worth of common stock, underpinned by the recent FDA approval of its lead product, DefenCath, which is an antimicrobial catheter lock solution aimed at reducing catheter-related bloodstream infections in patients undergoing hemodialysis. The common stock is listed on the Nasdaq Global Market under the symbol 'CRMD'. Investing in this stock involves specific risks outlined in the prospectus, including operational losses and dependency on the successful commercialization of their product. The underwriters are RBC Capital Markets, who have a 30-day option to purchase additional shares. Proceeds from this offering are intended for general corporate purposes, research and development, and potential strategic transactions. This prospectus supplement is part of a registration statement that is effective, and an extensive risk factor section advises investors to consider various uncertainties before investing. The document emphasizes the need for careful consideration of the associated risks and market volatility when making investment decisions. Additionally, compliance with regulations, reimbursement policies, and the market's reception of DefenCath may influence the company's financial future.